Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242641 | 0.90 | SCD (0.58) | SCDCD74MIFPKMROCK2 | |
| SCHEMBL14047397 | 0.81 | SCD (0.56) | SCDPKMROCK2HDAC1 | |
| SCHEMBL242539 | 0.80 | SCD (0.78) | SCD | |
| SCHEMBL242710 | 0.79 | SCD (0.61) | SCDROCK2 | |
| SCHEMBL245005 | 0.79 | SCD (0.60) | SCDHDAC1 | |
| SCHEMBL241054 | 0.78 | SCD (0.61) | SCDHDAC1 | |
| SCHEMBL243719 | 0.75 | SCD (0.76) | SCD | |
| SCHEMBL13555505 | 0.74 | PKM (0.55) | PKMROCK2ROCK1ABHD6CYP4F2 | |
| SCHEMBL348495 | 0.72 | SCD (0.56) | SCD | |
| SCHEMBL4565025 | 0.72 | SCD (0.68) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |